Harrow IncHROW
Price$30.61

Outlook & Key Dates

Estimates, guidance, catalysts, and upcoming events

Analyst Estimates Learn more →
Analyst Coverage
8analysts covering
Consensus: PositiveAs of 18 Aug 2026
FY Revenue (est.)
$350.8Mnext fiscal year
As of 18 Aug 2026
FY EPS (est.)
$0.28next fiscal year
As of 18 Aug 2026
Reporting Calendar
EventExpected Date
Q3 2026 Earnings Release9 Nov 2026
Monitoring Framework
Key Performance Indicators
VEVYE Total Prescriptions and Market Share QuarterlyTarget: Over $100 million in VEVYE revenue for full year 2026
Consolidated Revenue Quarterly44.2MTarget: $350 million to $365 million for FY 2026
Adjusted EBITDA Quarterly-12.7MTarget: $80 million to $100 million for FY 2026
Watch Items
  • VEVYE Gross-to-Net (GTN) Pricing and Deductible Modeling
  • IHEEZO Commercial Adoption and Net Pricing
  • MELT-300 Pipeline Progression
Sign in / Sign up to read more

Research as of 20 Jun 2026

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.